Hodgkin's Disease Clinical Trials
94 clinical trials for Hodgkin's Disease across international registries, including 4 currently recruiting participants. Compare status, phase, eligibility criteria and locations.
- Establishing a Tumor Bank in Families With Multiple Lymphoproliferative Malignancies — RECRUITING
- The Prospective Collection, Storage and Reporting of Data on Patients Undergoing Hematopoietic Stem Cell Transplantation Utilizing a Standard Preparative Regimen — RECRUITING
- Cytotoxic T-Lymphocytes for EBV-positive Lymphoma, GRALE — RECRUITING · PHASE1
- Clinical and Pathologic Studies in Non-Hodgkin's Lymphoma and Hodgkin's Disease — RECRUITING
- A Study of Bone Marrow Transplantation Using Fully-Matched Relatives as Donors for Patients With Hematological Malignancies — COMPLETED · PHASE2
- Autologous/Allogeneic TGFbeta-resistant LMP-specific CTL, Lymphoma (TGF-beta) — ACTIVE_NOT_RECRUITING · PHASE1
- Cardiac Screening in Survivors of Hodgkin's Disease Treated With Mediastinal Irradiation — ACTIVE_NOT_RECRUITING · NA
- Bone Marrow Transplantation of Patients in Remission Using Partially Matched Relative Donor — COMPLETED · PHASE2
- A Study of Nivolumab Plus Brentuximab Vedotin Versus Brentuximab Vedotin Alone in Patients With Advanced Stage Classical Hodgkin Lymphoma, Who Are Relapsed/ Refractory or Who Are Not Eligible for Autologous Stem Cell Transplant, — TERMINATED · PHASE3
- Safety and Efficacy of BL-8040 for the Mobilization of Donor Hematopoietic Stem Cells and Allogeneic Transplantation in Patients With Advanced Hematological Malignancies — COMPLETED · PHASE2
- A Phase II Study Evaluating the Safety and Efficacy of Subcutaneous Plerixafor — COMPLETED · PHASE2
- Hodgkin Lymphoma Molecular Profiling and Clinical Outcomes in U.S. Community Oncology Practices — COMPLETED
- Phase II Study of Filgrastim (G-CSF) Plus ABVD in the Treatment of HIV-Associated Hodgkin's Disease — COMPLETED · PHASE2
- Maintenance Rituximab With mTor Inhibition After High-dose Consolidative Therapy in Lymphoma — COMPLETED · PHASE2
- MSC and HSC Coinfusion in Mismatched Minitransplants — TERMINATED · PHASE2
- Pilot Study Evaluating Safety & Efficacy of DCBT: NiCord® & UNM CBU to Patients With Hematological Malignancies — COMPLETED · PHASE1
- A Study to Evaluate the Safety, Pharmacokinetics, and Hematopoietic Stem Cell Mobilization of TG-0054 Alone or in Combination With G-CSF in Patients With Multiple Myeloma, Non-Hodgkin Lymphoma or Hodgkin Disease — COMPLETED · PHASE2
- Stem Cell Transplant for Hematological Malignancy — TERMINATED · NA
- Phase I Vorinostat in Combination With Niacinamide and Etoposide for Lymphoid Malignancies — COMPLETED · PHASE1
- Trial of Donor Lymphocyte Infusion (DLI) and Activated DLI Following Relapse After Allogeneic Stem Cell Transplant — TERMINATED · PHASE1
- P3 Study of Umbilical Cord Blood Cells Expanded With MPCs for Transplantation in Patients With Hematologic Malignancies — COMPLETED · PHASE3
- A Study of SB-743921 in Non-Hodgkin Lymphoma and Hodgkin Lymphoma — COMPLETED · PHASE1
- Allogeneic Transplantation From Related Haploidentical Donors — COMPLETED · PHASE2
- Pharmacokinetics and Safety Study of Azacitidine in Cancer Patients With and Without Impaired Renal Function — COMPLETED · PHASE1
- Breast MRI Screening in Women Treated With Mediastinal Irradiation for Hodgkin's Disease — COMPLETED
- Rituxan + BEAM and Auto Stem Cell Transplant for High Risk Lymphoma or Hodgkin's Disease — COMPLETED · NA
- Alemtuzumab (Campath-1H) Monoclonal Antibody in Patients With Relapsed and Resistant Classical Hodgkin's Disease — WITHDRAWN · PHASE2
- Fludarabine Based Conditioning for Allogeneic Transplantation for Advanced Hematologic Malignancies — COMPLETED · NA
- Safety and Efficacy Study of I-131 Tositumomab in Patients With Relapsed/Refractory Hodgkin's Lymphoma — COMPLETED · PHASE1
- Donor Th2 Cells to Prevent Graft-Versus-Host Disease in Bone Marrow Transplants — COMPLETED · PHASE1
- Allogeneic Blood Stem Cell Transplantation and Adoptive Immunotherapy for Hodgkin's Disease — COMPLETED · PHASE2
- Immune Mobilization of Autologous Peripheral Blood Stem Cells Using Interleukin-2 and GM-CSF — COMPLETED · PHASE1
- Trial of Vorinostat in Combination With Cyclophosphamide, Etoposide, Prednisone and Rituximab for Elderly Patients With Relapsed Diffuse Large B-Cell Lymphoma (DLBCL) — COMPLETED · PHASE1
- Kinetic of Cytokines Decrease and Hodgkin Lymphoma Prognostic — COMPLETED · NA
- Evaluation of Late Treatment Effects in Long-Term Survivors of Hodgkin's Disease Previously Treated at NIH: A Multi-Institutional Trial — COMPLETED
- Safety Study of the Proteasome Inhibitor PR-171 (Carfilzomib for Injection) in Patients With Hematological Malignancies — COMPLETED · PHASE1
- Pentostatin and Alemtuzumab as a Preparative Regimen for Allogeneic Peripheral Blood Stem Cell Transplantation — TERMINATED · PHASE2
- Bendamustine HCL in Relapsed and Primary Refractory Hodgkin Lymphoma — COMPLETED · PHASE2
- Pilot Study Exploring the Use of Hyperbaric Oxygen in Autologous Peripheral Blood Stem Cell Transplantation — OTHER · NA
- Allogeneic Cytokine-induced Killer Immunotherapy for Relapse After Allogeneic Marrow Transplant for Haematological Malignancies — COMPLETED · PHASE1
- T-Cell Depleted Allogeneic Stem Cell Transplantation for Patients With Hematologic Malignancies — COMPLETED · PHASE2
- Single Treatment With FT1050 of an Ex-vivo Modulated Umbilical Cord Blood Unit — COMPLETED · PHASE1
- Umbilical Cord Blood Transplant for Hematological Malignancies — COMPLETED · PHASE1
- Study of Unrelated Cord Blood Transplantation Using Tacrolimus and Sirolimus — COMPLETED · PHASE2
- Safety Study Looking at the Use of a Natural Killer Cell Line Against Hematological Malignancies — COMPLETED · PHASE1
- Registry Study of T Cell Depleted Allo Non-Myeloablative Stem Cell Transplant — COMPLETED
- Quality of Life Among Survivors of Hodgkin Lymphoma — COMPLETED
- Basiliximab #2: In-Vivo Activated T-Cell Depletion to Prevent Graft-Versus_Host Disease (GVHD) After Nonmyeloablative Allotransplantation for the Treatment of Blood Cancer — COMPLETED · PHASE2
- Rituximab (Rituxan) for the Prevention of EBV-LPD Epstein Barr Virus (EBV) Lymphoproliferative Disorder Post T Cell Depleted Unrelated and HLA Mis-matched Related HSCT — COMPLETED · NA
- Total Body Irradiation/Fludarabine Based Ablative Haploidentical Transplant for Hematologic Diseases — COMPLETED · PHASE2
Refine this search